Key result
High-dose doxorubicin is linked to ~30% cardiotoxicity risk, driven by oxidative stress and mitochondrial dysfunction.
Why the study?
Clinical application of doxorubicin is severely limited by dose-dependent cardiotoxicity, prompting a review of recent insights into its molecular mechanisms, biomarkers, and management.
Design
Literature review
Authors
Loading...
Warrants vigilance for cardiotoxicity above 550 mg/m² doxorubicin; leaves open optimal mitigation strategies for prospective validation.
This review highlights the molecular mechanisms of doxorubicin-induced cardiotoxicity, emphasizing oxidative stress and mitochondrial dysfunction, and discusses potential mitigation strategies.
Amaan et al. (2024) conducted a review in Doxorubicin-induced cardiotoxicity. Doxorubicin was evaluated. Doxorubicin is associated with a 26-36% risk of cardiotoxicity at cumulative doses above 550 mg/m², primarily driven by oxidative stress and mitochondrial dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: